

LycoMab™ – a monoclonal antibody vector to deliver and potentiate anti-proliferative and pro-apoptotic lycopene to treat prostate cancer

Prostate cancer is one of the leading forms of male cancer and cancer-related mortality. There is a need to develop new therapeutic approaches to treat this disease.

It has been established *in vitro* that *trans*-lycopene has an anti-proliferative effect and can also trigger apoptosis of cancer cells, including prostate cancer. Although the prostate has a significant level of expression of carotenoid receptors, patients with prostate cancer have a lycopene deficiency, in particular in affected tissues.

LycoMab™ is a new approach, not only to facilitate delivery of lycopene to the prostate, but also potentially co-deliver other synergetic pharmaceuticals for the treatment of the prostate and other forms of cancer.

Structure and Functionality

LycoMab™ is a mouse monoclonal IgM antibody mAb 6B9 against *trans*-lycopene. Its complex with lycopene has the ability to bind with two different sites on the cellular membrane - carotenoid and Fc-one. This would provide an additional delivery level of lycopene into the cells.


Moreover, IgM is a polyvalent molecule and can bind up to five ligands. This provides an opportunity to create a hybrid platform constructed from immunoglobulins of different specificity. For example, LycoMab™ with an incorporated Fab fragment from another antibody, which is capable of binding another synergetic anti-cancer pharmaceutical, would be able to carry and concentrate this molecule together with lycopene in the prostate.

In addition, the potential of the hybrid LycoMab™ could be further potentiated and extended by co-hybridisation with tissue cancer specific antibodies.

Vector for Intracellular Delivery of Lycopene

In a B10.MLM cell culture experiment it was demonstrated that immune complexes of mAb 6B9 with *trans*-lycopene could provide a significantly higher intracellular level than when this carotenoid was incubated at the same concentration but in a free form, fig. 1.

Figure 1. Lycopene concentration in microsomal fraction after 16 hours of incubation




Promotion of Anti-Proliferative and Pro-Apoptotic Lycopene in Prostate Cancer Cell

A series of in vitro experiments were undertaken on prostate adenocarcinoma cancer cell culture PC-3. It was demonstrated that the apoptotic cell death rate at 72 hours of treatment with 1 μ M *trans*-lycopene, or with its blend with irrelevant IgM, was 19-21%. At the same time point the cell death rate for treatment with the same concentration of lycopene, but in the form of its immune complex LycoMabTM, was 48%.

A similar potentiating effect was observed in all concentrations of lycopene studies, 2, 4, 8 and 16 μ M. The results obtained with propidium iodide staining (fig. 2) were in good agreement with the cell viability assay.

Figure 2. Propidium iodide staining of PC3 cells incubated with LycoMab lycopene 8 μ M, 48h; fluorescent microscopy at 535nm, \times 1000



Ivan M Petyaev, Naylia A Zigangirova, Valery A Tsibezov, Elena Y Morgunova, Nigel H Kyle, Elena D Fedina, Yuriy K Bashmakov - ASSOCIATION WITH MONOCLONAL ANTIBODY PROMOTES ANTI-PROLIFERATIVE AND PRO-APOPTOTIC EFFECTS OF LYCOPENE IN PROSTATE CANCER CELLS. Submitted for Publication (2018).

Next Step

The main objective at the next step is to find funding and/or partners to take LycoMabTM to an animal study programme and expand its pre-clinical dossier.

For more information and enquiries please contact: info@lycotec.com

Granta Park, McClintock Building, Great Abington,
Cambridge CB21 6GP
Phone: +44 (0)1223 651411
www.lycotec.com